News
2 mars 2023
Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab.
Read more
An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease.
“An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease”, Radford-Smith D., Hageman I.L., Joustra V., Li Yim A.Y.F., Davids M., Henneman P., Hakvoort T., D’Haens G., de Jonge W.J., Anthony DC., Satsangi J., Probert F., on behalf of the EPIC-Pioneer consortium, Journal of Crohn’s and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i257–i259, https://doi.org/10.1093/ecco-jcc/jjab232.325.
For more information, please visit the BIOCYCLE project website at https://biocycle-project.eu/ EU reference: grant agreement No 633168 – BIOCYCLE (PHC-13-2014).